Bg pattern

AMBROXOL STADA 6 mg/ml SYRUP

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use AMBROXOL STADA 6 mg/ml SYRUP

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Patient Information: Summary of Product Characteristics

Ambroxol Stada 6 mg/ml Oral Solution

Read this entire leaflet carefully before starting to take this medication, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, consult your doctor or pharmacist.
  • This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
  • If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Contents of the Leaflet

  1. What is Ambroxol Stada and what is it used for
  2. What you need to know before taking Ambroxol Stada
  3. How to take Ambroxol Stada
  4. Possible side effects
  5. Storage of Ambroxol Stada
  6. Package contents and additional information

1. What is Ambroxol Stada and what is it used for

Ambroxol Stada contains the active ingredient ambroxol hydrochloride, which belongs to the group of medications called mucolytics. It is used to facilitate the elimination of mucus from the respiratory tract in conditions with thick mucus (expectorant).

Ambroxol Stada is indicated for the treatment of mucus dissolution in bronchial and pulmonary conditions with thick mucus in adults, adolescents, and children from 2 years of age.

You should consult a doctor if your symptoms worsen or do not improve after 4-5 days.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before taking Ambroxol Stada

Do not take Ambroxol Stada:

  • If you are allergic to ambroxol hydrochloride or any of the other components of this medication (listed in section 6).
  • In children under 2 years of age.

Warnings and precautions

Consult your doctor or pharmacist before starting to take Ambroxol Stada.

If you have kidney or liver problems, consult your doctor before using Ambroxol Stada.

If you suffer from a rare bronchial disease with increased mucus accumulation (e.g., primary ciliary dyskinesia), where the mucus cannot be transported out of the lungs, take Ambroxol Stada only under medical supervision.

In acute respiratory conditions, if you notice a worsening of symptoms or lack of improvement after 4-5 days of treatment, stop treatment with Ambroxol Stada and consult your doctor immediately.

There have been reports of severe skin reactions associated with the administration of ambroxol hydrochloride. If you experience a skin rash (including lesions of the mucous membranes, such as the mouth, throat, nose, eyes, and genitals), stop using Ambroxol Stada and consult your doctor immediately.

Children

Ambroxol Stada should not be used in children under 2 years of age.

Other medications and Ambroxol Stada

Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.

No adverse interactions of Ambroxol Stada with other medications are known.

Do not use ambroxol with medications for dry cough.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

No adverse effects have been observed during pregnancy. However, Ambroxol Stada should not be taken during the first trimester of pregnancy.

Ambroxol hydrochloride is excreted in breast milk, so Ambroxol Stada is not recommended during breastfeeding.

Driving and using machines

There are no studies on the effects of Ambroxol Stada on the ability to drive and use machines. However, there is no evidence that this medication affects the ability to drive and use machines.

Ambroxol Stada contains sorbitol

This medication contains 245 mg of sorbitol (E420) per ml. Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to certain sugars, or you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disease, consult your doctor before taking this medication.

Ambroxol Stada contains benzoic acid

This medication contains 1.75 mg of benzoic acid per ml. Benzoic acid may increase the risk of jaundice (yellowing of the skin and eyes) in newborns (up to 4 weeks of age).

Ambroxol Stada contains propylene glycol

This medication contains 1.59 mg of propylene glycol per ml. If your baby is under 4 weeks of age, consult your doctor or pharmacist, especially if your baby has been given other medications that contain propylene glycol or alcohol.

3. How to take Ambroxol Stada

Follow the instructions for administration of the medication contained in this leaflet or as indicated by your doctor or pharmacist. If you have any doubts, ask your doctor or pharmacist.

The recommended dose is:

Adults and adolescents over 12 years

5 ml, 3 times a day for 2-3 days

then:

5 ml, 2 times a day.

Children from 6 to 12 years

2.5 ml, 2-3 times a day

Children from 2 to 5 years

1.25 ml, 3 times a day

Children under 2 years

Ambroxol Stada should not be used in children under 2 years of age.

Method of administration

To facilitate the administration of the syrup, the package contains a measuring spoon.

Ambroxol Stada can be taken with or without food.

Duration of use

Treatment should not exceed 4-5 days without consulting a doctor.

If you take more Ambroxol Stada than you should

No cases of overdose with Ambroxol Stada are known.

According to reports of accidental overdose and/or medication errors, the observed symptoms are consistent with the side effects of Ambroxol Stada when taken at the recommended dose, and symptomatic treatment may be necessary.

In case of overdose or accidental ingestion, consult your doctor or pharmacist, or call the Toxicology Information Service, phone 915 620 420, indicating the medication and the amount ingested.

If you forget to take Ambroxol Stada

Do not take a double dose to make up for forgotten doses.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone will experience them.

If you experience any of the following side effects, stop taking Ambroxol Stada immediately and consult your doctor:

Unknown frequency (cannot be estimated from available data)

  • anaphylactic reactions including anaphylactic shock, angioedema (rapidly progressing skin, subcutaneous tissue, mucous membrane, or submucosal tissue swelling) and pruritus
  • severe adverse skin reactions (such as erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis, and acute generalized exanthematous pustulosis)

Other side effects that may occur:

Frequent (may affect up to 1 in 10 people):

  • nausea
  • decreased sensitivity of the mouth and throat (hypoesthesia)
  • altered sense of taste

Uncommon (may affect up to 1 in 100 people):

  • vomiting, diarrhea, dyspepsia, abdominal pain
  • dry mouth
  • fever
  • mucous membrane reactions

Rare (may affect up to 1 in 1,000 people):

  • hypersensitivity reactions
  • exanthema, urticaria
  • throat dryness

Reporting side effects:

If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of Ambroxol Stada

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date stated on the label and carton after EXP. The expiration date is the last day of the month indicated.

This medication does not require special storage conditions.

Shelf life after first opening: 6 months.

Medications should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medication in the pharmacy's SIGRE collection point. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.

6. Package contents and additional information

Composition of Ambroxol Stada

  • The active ingredient is ambroxol hydrochloride. Ambroxol Stada contains 30 mg of ambroxol hydrochloride per 5 ml of syrup.

Each ml of Ambroxol Stada contains 6 mg of ambroxol hydrochloride.

  • The other ingredients are: Hydroxyethylcellulose, Sorbitol liquid (non-crystallizing) (E420), Glycerol (85 percent) (E422), Benzoic acid (E210), Acesulfame potassium, Strawberry flavor (Propylene glycol (E1520), Glycerol, 2-ethyl-3-hydroxy-4-pyron, Ethyl lactate, Methyl cinnamate, Butyric acid, 2-methylbutyric acid, Hexanoic acid, Butanedione), Vanilla flavor (Caramel color (E150d), Propylene glycol (E1520)) and Purified water.

Appearance of the product and package contents

Ambroxol Stada is a clear, almost colorless, slightly viscous syrup presented in a brown glass type III bottle with a white polyethylene tamper-evident cap and a child-resistant closure system.

It is available in the following sizes: 100 ml, 125 ml, 200 ml, or 250 ml of syrup.

Not all package sizes may be marketed.

Marketing authorization holder

Laboratorio STADA, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern (Barcelona)

Spain

Manufacturer

STADA Arzneimittel AG

Stadastrasse 2 – 18

61118 Bad Vilbel, Germany

STADA Arzneimittel GmbH

Muthgasse 36/2

1190 Vienna, Austria

Laboratórios Basi - Indústria Farmacêutica, S.A.

Parque Industrial Manuel Lourenço Ferreira, Lotes 8, 15 e 16, Mortágua

3450-232, Portugal

This medication is authorized in the Member States of the European Economic Area under the following names:

AT Ambroxol Stada 30 mg/5 ml Syrup

DE Ambroxolhydrochlorid AL 30 mg/5 ml Syrup

ES Ambroxol Stada 6 mg/ml Oral Solution

Date of last revision of this leaflet: March 2019

Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.

Online doctors for AMBROXOL STADA 6 mg/ml SYRUP

Discuss questions about AMBROXOL STADA 6 mg/ml SYRUP, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for AMBROXOL STADA 6 mg/ml SYRUP?
AMBROXOL STADA 6 mg/ml SYRUP requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in AMBROXOL STADA 6 mg/ml SYRUP?
The active ingredient in AMBROXOL STADA 6 mg/ml SYRUP is ambroxol. This information helps identify medicines with the same composition but different brand names.
Who manufactures AMBROXOL STADA 6 mg/ml SYRUP?
AMBROXOL STADA 6 mg/ml SYRUP is manufactured by Laboratorio Stada S.L.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of AMBROXOL STADA 6 mg/ml SYRUP online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether AMBROXOL STADA 6 mg/ml SYRUP is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to AMBROXOL STADA 6 mg/ml SYRUP?
Other medicines with the same active substance (ambroxol) include AMBROXOL ALDO-UNION 15 mg/2 ml ORAL SOLUTION OR CONCENTRATE FOR NEBULIZER INHALATION, AMBROXOL CINFA 3 mg/ml SYRUP, AMBROXOL CINFA 6 mg/ml SYRUP. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media